Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study

Abstract

In an unselected cohort of patients with AF, antiarrhythmic treatment with flecainide, propafenone, sotalol, or amiodarone was not associated with increased risk of death. From a safety perspective, this indicates appropriate selection of patients for AAD therapy.